Cancer Drug Target Validation

Led by a group of expert scientists, Frontage has expertise in cancer drug discovery and development.

• Cancer molecular target genetic screening
• Cancer cell biology and pharmacology
• Patient-derived orthotopic sub-renal capsule xenograft mouse model development
• Unique In vivo DM/PK/ADME characterization of “drug-like” properties in patient-derived xenograft
• Integrated LC/MS/MS and biological assays supporting discovery and IND and NDA-enabling development studies

ANTI-CANCER DRUG DISCOVERY & DEVELOPMENT

In Vitro Cell Line Anticancer Activity Screening

• Drug efficacy screening assays using commercial ATCC human cancer cell lines with known genetic characteristization

In Vivo Cell Line Xenograft Drug Efficacy Study

• Utilize commercial cell lines or cell line provided by sponsor to generate subcutaneous, subrenal capsule or other orthotopic xenograft models for drug efficacy studies
• Generate pharmacokinetic data from the same experiment based on serial blood sampling for LC/MS/MS assay to provide PK/PD correlation

In Vivo Patient-Derived Orthotopic Xenograft Translational Efficacy Study

• Translational efficacy study based on patient-derived tumors established in NOD-SCID mice
• Highly recognized expertise and excellent track record on development of patient-derived tumor xenografts of various cancers including cancers the prostate, ovary, lung, pancreas, skin, uterus, colon, kidney, bone, breast sarcoma and lymphoma
• Generate pharmacokinetic data from the same experiment based on serial blood sampling for LC/MS/MS assay to provide PK/PD correlation

Uniquely Integrated In Vivo Anticancer Drug Efficacy Study Design

• Inhibition of tumor growth and metastases efficacy endpoints
• Pharmacokinetics and ADME data for PK/PD correlation
• Survival endpoint and adverse events monitoring
• Histopathological evaluation
• Molecular targets and biomarker evaluation